IE 11 is not supported. For an optimal experience visit our site on another browser.

Exmovere Holdings Partners With Renell Bank for Frankfurt Stock Exchange Listing

/ Source: GlobeNewswire

MCLEAN, Va., Sept. 21, 2010 (GLOBE NEWSWIRE) -- Exmovere Holdings, Inc., ( ) a biomedical engineering company, today announced that they will shortly be listed on the First Quotation Board (Open Market) of the Frankfurt Stock Exchange. The company's official listing sponsor is Renell Wertpapierhandelsbank AG.

David Bychkov, CEO of Exmovere Holdings, Inc., stated: "Renell has pre-approved Exmovere in writing and confirmed that they would take on the role of being our listing partner. This registered securities trading bank ranks amongst the very top players in its field in Germany and we are more than confident with our decision to partner with this firm."

For more information on Renell, please visit:

Given where the company is in executing their business strategy and moving their products forward, listing in Frankfurt will allow for additional awareness and liquidity. Although it is unusual for American companies to seek their primary listings overseas, this move will give Exmovere global exposure to investors and will allow for the company to maintain its US identity and corporate base in Virginia.

The Frankfurt Stock Exchange is one of the world's largest trading centers for securities. Germany has seven stock exchanges and the Frankfurt Stock Exchange is the largest of these exchanges.  Operated by Deutsche Boerse AG, the Frankfurt Stock Exchange facilitates advanced electronic trading, settlement and information systems which will allow for Exmovere to meet the steadily growing demands of cross border trading.

Although the Frankfurt Stock Exchange has floor trading, its electronic trading system Xetra is one of the leading electronic trading platforms in the world. Out of the 300 participants on this exchange, nearly 50% come from abroad which is why it has established such a favorable reputation with global investors.

For more information on the Frankfurt Stock Exchange and Xetra, please visit:

The core emotion technologies of Exmovere Holdings originated at the now defunct Universita' dell Immagine (UI) in Milan, Italy where David Bychkov, the CEO of Exmovere, was a professor and director of the Laboratory of Psychophysiology from 1999-2006. At UI, Bychkov collaborated with fellow researcher Dr. William Giroldini on the development of emotion algorithms and embedded biosensors. Because of these European roots, Exmovere's substantial base of international shareholders and the growing waiting list of customers for the company's forthcoming Exmobaby, Telepath and Chariot products in Europe, the Frankfurt Stock Exchange is an ideal place for the company to seek a primary listing.

According to Cheyenne Crow, VP and COO of Exmovere, "The company may one day seek a secondary listing on an exchange in the US in the future, however, the Frankfurt exchange makes the most sense for the company right now. It creates a global marketplace for our shareholders."

David Bychkov, CEO of Exmovere, added, "We are fulfilling commitments we have made to our shareholders. Our management team would like them to enjoy the visibility and credibility associated with an exchange of this caliber. Frankfurt is the right exchange for Exmovere to start, stay, and grow as a publicly listed company."

Exmovere Holdings, Inc. is focused on government and consumer applications for healthcare, mobility, and security and the practical applications of the study of human emotion. Exmovere is currently developing emotion-monitoring infant sleepwear, wireless biosensor wristwatches and sensor-enhanced mobility devices for the disabled. The company also offers Internal Medicine services to over 2000 active patients through its subsidiary, Clinica of Virginia, LLC. Clinica represents a major component of Exmovere's ongoing effort to push forward its message that human emotion is a predictor of forward behavior patterns. Further inquiries into the company, its strategic vision for Clinica or any of its innovative products can be directed to the below.

The Exmovere Holdings, Inc. logo is available at

Certain of the above statements contained in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Actual results, events, and circumstances (including future performance, results, and trends) could differ materially from those set forth in such statements due to various factors, risks, and uncertainties, including, but not limited to, risks associated with the company's future growth and operating results, the uncertainty of market acceptance of the company's products, technological change, competitive factors, and general economic conditions. Except as otherwise required to be disclosed in periodic reports required to be filed by companies registered under the Exchange Act by rules of the Securities and Exchange Commission, the company has no duty and undertakes no obligation to update such statements.

CONTACT: Exmovere Holdings, Inc. Heather Olson, Assistant Vice President, Investor Relations (703) 245-8513